Detecting common mutations in MM patients through liquid biopsy

The detection of various gene mutations, such as those in Ras and Raf, are important for risk stratification and identifying appropriate treatment plans for multiple myeloma (MM) patients. This geneti... Author: VJHemOnc Added: 12/06/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts

Related Links:

I realize it’s been quite some TIME since I’ve written a post, almost a MONTH!, so today I decided to sit down and write one, and it’s going to be a long one, so get yourselves some tea and get comfy…    CHAPTER ONE. PEEKABOO: in September I spent a lot of time researching possibly helpful but definitely non-toxic treatments for Peekaboo, my 11-year-old kitty whom I’ve written a lot about in recent times. She has a slipped disc, basically, and has been having a VERY hard time walking. The risk, of course, is that she’d stop walking altogether. Couldn’t let that happen! I...
Source: Margaret's Corner - Category: Cancer & Oncology Authors: Tags: Blogroll Source Type: blogs
ConclusionsPrompt and appropriate laboratory investigations ensure correct diagnosis of pseudohyperphosphatemia and help clinicians properly manage patients. To our knowledge, this patient is the first reported case of pseudohyperphosphatemia in patients with progression from SMM to MM.
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research
Condition:   Multiple Myeloma Intervention:   Biological: IM21 CART Sponsors:   Peking Union Medical College Hospital;   Beijing Immunochina Medical Science&Technology Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Refractory Plasma Cell Myeloma Interventions:   Drug: Dexamethasone;   Biological: Elotuzumab;   Drug: Pomalidomide Sponsors:   Mayo Clinic;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.8b00880
Source: Molecular Pharmaceutics - Category: Drugs & Pharmacology Authors: Source Type: research
British Journal of Haematology, EarlyView.
Source: British Journal of Haematology - Category: Hematology Authors: Source Type: research
Condition:   Multiple Myeloma Interventions:   Drug: Daratumumab;   Drug: velcade;   Drug: Lenalidomide;   Drug: dexamethasone Sponsors:   European Myeloma Network;   Janssen Research & Development, LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma Interventions:   Procedure: CS1-CAR T Therapy;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Leukapheresis Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Cancer (Colon Cancer, Breast Cancer, Lymphoma, Multiple Myeloma);   Elderly;   Antineoplastic Agents;   Cardiotoxicity Interventions:   Other: Intensive cardiovascular monitoring;   Other: No intervention Sponsors:   Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León;   IBSAL-Instituto de Investigación Biomédica de Salamanca, Fundación IECSCYL-IBSAL;   Instituto de Salud Carlos III Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Multiple Myeloma;   Relapsed and Refractory Multiple Myeloma Intervention:   Drug: HG146 Sponsor:   HitGen Ltd Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Genetics | Myeloma